By Kevin Dunleavy
While the global sales rankings of Big Pharma's superstar drugs naturally feature the biggest names in the business, several new meds popped up on the list this year because of the coronavirus. Pfizer's COVID-19 vaccine displaced AbbVie's Humira at the top slot, which the immunology drug had held for nearly a decade.
read more
By Nick Paul Taylor
GSK is betting big to reenergize its fight for a share of the pneumococcal vaccine market, agreeing to pay $2.1 billion upfront to acquire Affinivax for a challenger to Pfizer’s blockbuster Prevnar franchise.
read more
By Dave Muoio
Although the deal is still subject to "various conditions," the new publicly traded entity would consist of 252 home health and 99 hospice locations.
read more
By Kevin Dunleavy
Babies that have spinal muscular atrophy now have an at-home treatment option that can help extend their lives. The FDA’s approval of Roche’s Evrysdi opens the oral drug up for infants younger than 2 months old.
read more
By Andrea Park
Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut.
read more
By James Waldron
RhoVac’s attempt to develop the first antigen vaccine for prostate cancer has ended in a phase 2 trial failure and forced the Swedish biotech to initiate cost-cutting measures. RV001, also known as onilcamotide, failed to significantly prevent or delay the progression of prostrate cancer.
read more
By Angus Liu
Bristol Myers Squibb’s Opdivo and Merck & Co.’s Keyturda have been duking it out for years across various tumor types. Now, BMS has scored a duo of FDA nods to level the playing field in esophageal cancer.
read more
By Gabrielle Masson
Positive phase 3 trial results have maintained momentum for Axsome Therapeutics' convoluted depression drug application, less than a month after the FDA rejected the company's migraine treatment.
read more
By Dave Muoio
While a mid-year redetermination was deemed unfeasible, HHS Secretary Xavier Becerra said Medicare's Aduhelm cost savings would be passed on to enrollees via lower rates in 2023.
read more
By Andrea Park
As Altoida’s Alzheimer’s disease screening platform inches closer to FDA clearance, the company is bulking up its clinical team. And to lead the way, it's chosen someone who's worked in Alzheimer's at two major drugmakers.
read more
By Heather Landi
Retail drugstore giant CVS is rolling out a virtual care service that gives consumers access to primary care, on-demand care, chronic condition management and mental health services.
read more
